Navigation Links
Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
Date:1/24/2010

aring alternative to oxaliplatin for the first-line treatment of metastatic CRC in 101 patients who had not received prior chemotherapy.  The trial's primary objective was to measure the relative incidence and severity of neuropathy in the FOLPI regimen compared to the FOLFOX regimen.  In addition, the study measured comparative safety and efficacy (assessed by disease control, progression-free survival (PFS) and overall survival (OS)) data; however, the study was not powered to assess the statistical significance of these secondary endpoints.  The final Phase 2 data indicated that:

  • FOLPI is associated with a statistically significant reduction in neurotoxicity compared to FOLFOX (HR <0.30; p <0.004).  Neuropathy, regardless of Grade, was 26 percent in FOLPI-treated patients and 62 percent in FOLFOX-treated patients. No Grade 3/4 neuropathy was observed with FOLPI.
  • FOLPI had similar efficacy to FOLFOX as measured by:
    • Disease Control of 75 percent and 76 percent for FOLPI and FOLFOX, respectively; (Relative risk 1.02 (95 percent Confidence Interval (CI) 0.79-1.32), p=0.9)
    • PFS of 6.8 months and 7.0 months for FOLPI and FOLFOX, respectively: HR 0.95 (95 percent CI 0.63-1.45), p=0.82
    • OS of 13.6 months and 15.6 months for FOLPI and FOLFOX, respectively: HR 1.17 (95 percent CI 0.72-1.91), p=0.53
  • Six-month and one-year survival rates were 80 percent and 52 percent for FOLPI and 83 percent and 55 percent for FOLFOX, respectively.
  • More patients who discontinued FOLFOX had associated neuropathy; neurotoxicity was not dose-limiting for FOLPI.  More patients who discontinued FOLPI had associated hematological events than with FOLFOX.
  • No hypersensitivity, cardiac or nephrotoxicity was observed with FOLPI or FOLFOX.
  • FOLPI had more frequent and severe, but manageable, thrombocytopenia an
    '/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  ConvaTec, a privately-held ... Nigel Clerkin has been appointed chief financial officer ... Mr. Clerkin was previously executive vice president and chief ... -based biotechnology company.  Mr. Clerkin was part of ... at Elan, culminating in its sale to Perrigo, a ...
(Date:7/22/2014)... 22, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... R&D outsourcing company with operations in China ... announced that it will release financial results for the second ... on Wednesday, August 13, 2014 (which will be Thursday morning, ... available on the investor relations section of the Company,s website ...
(Date:7/22/2014)... , July 22, 2014  According to the ... their children spend on digital devices. An AOA survey ... of 10 and 17 estimate they use an electronic ... a separate AOA survey of parents revealed that only ... electronic device for that same amount of time. Eye ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4
... Medicated Arthri-Zen Relief Cream(R) Clinically Shown to Work for up ... Americans suffer from the aches and pains that come with ... effective ways to get fast relief from arthritis pain is ... the relief tends to be short-lived. Many people find that ...
... economic slowdown, America,s pharmaceutical research and biotechnology companies ... the research and development of new life-changing medicines ... billion from 2007, according to analyses by the ... Burrill & Company. PhRMA-member companies alone invested ...
Cached Medicine Technology:Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain 2Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain 3R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 3R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 4
(Date:7/22/2014)... a popular supplier of wedding dresses and special occasion gowns ... party dresses to its product category. Additionally, the supplier ... its website. As a special offer, all customers who place ... discounted rate, up to 54% off. , A lot of ... marketing specialist believes the new white party dresses will be ...
(Date:7/22/2014)... As one alternative to surgery, a handful ... now reduce or in some cases eliminate dark eye ... buying guide to help buyers find products to remove ... This guide is meant for both women and men ... circles that can appear. While some people inherit this ...
(Date:7/22/2014)... July 23, 2014 Marietta, Georgia and surrounding ... homes. In an efforts to lower population of needy ... from the Tigg Neuter Project have joined forces. Local ... All proceeds will be presented to the Tigg Neuter ... animal clinic family are excited to attend and host the ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 DocbookMD ... process of deploying one of the largest physician-centric mobile ... ( MHMD ) in Houston. , Created by Austin-based ... the DocbookMD application will be embedded into MHMD’s Accountable ... searched for the best technology to put this capability ...
(Date:7/22/2014)... 22, 2014 Obtaining a bachelor’s degree ... veterans who have hands-on medical experience. The School of ... today announced the launch of an accelerated nursing degree ... The new program, the UNCG Veterans Access Program (VAP), ... 24 veterans. With some prior college credit, veterans who ...
Breaking Medicine News(10 mins):Health News:Elegant White Party Dresses Now Provided by Distinguished Company iFitDress.com 2Health News:Remove Dark Circles Under Eyes: New Cosmetic Buying Guide Released Online for Men and Women 2Health News:Marietta Vet Clinic Hosts 2014 Dog Days of Summer Pet Rescue Event 2Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 2Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 3Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 4Health News:UNCG School of Nursing Fast-Tracks Medically Trained Veterans 2
... to help spread awareness of Foundation,s mission and servicesSHORT ... Reeve Foundation, the national, non-profit organization dedicated to finding ... the lives of people living with paralysis, announced today ... popular show "Brothers and Sisters," has been named a ...
... people over 20 now have the condition, while 30% are ... The most recent analysis of data on diabetes in the ... 20 and older have the condition, 40 percent of whom ... diagnosed patients than noted in a previous study, although the ...
... A three-year award from the U.S. Department ... Affairs to Georgetown University,s Institute for Reproductive Health ... and Massachusetts to offer the Standard Days Method, ... developed by Institute researchers. , In addition to ...
... D.Sc., co-founder and CEO of Arobella Medical, LLC, a ... fundamentals of ultrasound assisted wound treatment at the 1st ... Congres in Paris, France on January 19, 2009. ... low frequency, therapeutic ultrasound and wound healing.In his presentation, ...
... the common cardiac drug clopidogrel following a heart attack ... if they are also taking widely used acid-lowering medications ... in CMAJ has found ( http://www.cmaj.ca/cgi/rapidpdf/cmaj.082001 ). ... of heart attack patients aged 66 years and older, ...
... 28 McGraw-Hill Professional, a leading global provider ... communities, and JAMA, the world,s most widely circulated ... launch of a new state-of-the-art digital resource, JAMAevidence. ... educators, and clinicians with the fundamental tools required ...
Cached Medicine News:Health News:Dave Annable Named Christopher & Dana Reeve Foundation Ambassador 2Health News:Diabetes Keeps Rising Among U.S. Adults 2Health News:Diabetes Keeps Rising Among U.S. Adults 3Health News:Bringing easy-to-use, effective natural family planning to American women 2Health News:Arobella Medical CEO Speaks at International Wound Care Conference in Paris 2Health News:Proton pump inhibitors increase risk of heart attacks for patients on common cardiac drug 2Health News:McGraw-Hill Professional and JAMA Launch New Online Evidence-Based Medicine, Clinical and Educational Resource 2Health News:McGraw-Hill Professional and JAMA Launch New Online Evidence-Based Medicine, Clinical and Educational Resource 3
... This is an enzyme immunoassay(EIA) ... antibodies to extractable nuclear antigens Sm, ... in human serum. The results from ... an aid in the diagnosis of ...
... designed with the proper sensitivity and specificity ... of autoimmune disease. Sera from over 2,000 ... individuals were tested during the development of ... compared the results to reference methods such ...
The K-ASSAY Rheumatoid Factor Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assay for quantifying...
Total IgE Control...
Medicine Products: